Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METorMET²: Methotrexate vs. Methotrexate + Metformin in Methotrexate‑naive Rheumatoid Arthritis
2018-004287-56Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in rheumatoid arthritis (RA) comparing Methotrexate monotherapy with Methotrexate + metformin (2 arms). Primary endpoint: Primary: Change in RA disease activity (DAS28). Started Jan 2020; status: active.
02
Drugs
methotrexatemetformin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-004287-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004287-56.